GSK to profile new class of antibiotic at Nov. 3 investor day
0
LONDON (Reuters) - British pharmaceutical company GlaxoSmithKline will profile its drug development pipeline, including a new class of antibiotic, on Nov. 3, its chief executive said on Thursday.